The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert advisory committee that advises United Kingdom health departments on immunisation, making recommendations concerning vaccination schedules and vaccine safety. It has a statutory role in England and Wales, and health departments in Scotland and Northern Ireland may choose to accept its advice.
History
The committee was established in 1963, having been until then an advisory board for polio immunisation. It gained statutory status as the Standing Advisory Committee on Vaccination and Immunisation, a non-departmental public body advising the Secretary of State for Social Services and the Secretary of State for Wales, under the National Health Service (Standing Advisory Committees) Order 1981.
Since the devolution of government powers to Wales, the JCVI continues to advise Welsh ministers. For England, the Health Protection (Vaccination) Regulations 2009 require the Secretary of State for Health to implement the committee's recommendations regarding national immunisation programmes. The committee has no statutory role in Scotland or Northern Ireland, although the Scottish Parliament takes JCVI advice because it has not formed an alternative body. In 2015 a petition was presented to the Scottish Parliament to depart from JCVI advice because the petitioner felt that the chair of the JCVI was not observing the Nolan Principles. Petitioner had contacted Nicola Sturgeon during her time as Health Minister, and nine years later had decided to petition as a last resort for his proposal to form a body "similar if not the same as Norway's model".
Following the government's review of public bodies that completed in 2012, the JCVI was reconstituted as a departmental expert committee, although its statutory status under the 1981 order continues.
Roles and responsibilities
The JCVI has a responsibility to provide high quality and considered advice and recommendations to the UK Health Ministers. This includes giving advice on recommendations on matters of both a 'routine' nature and also on any specific or special matters that Ministers may request. In formulating any advice and recommendations, the Committee must take into account the need for and impact of vaccines, the quality of vaccines and the strategies to ensure that their greatest benefit to the public health can be obtained from the most appropriate use of vaccines.
JCVI members meet and report as one Committee, usually three times a year. Its recommendations, as accepted by the secretaries of state, are published in "Immunisation against infectious diseases", commonly referred to as The Green Book which provides guidance to clinicians, and also through other routes as necessary (e.g., the Chief Medical Officer letters).
Membership
In June 2018, the JCVI chair was Professor Andrew Pollard of the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford.
The chair of the COVID-19 subcommittee is Wei Shen Lim, a consultant respiratory physician and honorary professor of medicine at Nottingham University Hospitals NHS Trust.
The current members' names and affiliations are published online although year of appointment is not stated. According to the published code of practice, appointments are normally of three years' duration. In accordance with the Code of Practice issued by the Commissioner for Public Appointments, members cannot serve on the Committee for more than 10 years.
A previous chairman, Andrew Hall, was appointed Knight Bachelor in the 2013 Birthday Honours.
Notable work
Position on MMR (1988 onwards)
The JCVI "expressed concern" about giving triple vaccines to children with a personal or family history of convulsions, but considered it appropriate to proceed with a planned introduction of the MMR vaccine in October 1988, including two products containing Urabe strain. After the start of the mass MMR immunisation programme, additional evidence that the strain was linked with viral meningitis surfaced in a number of countries, and by 1990, many had withdrawn products containing it. In November 1992, it was withdrawn in the UK, following the publication of government-sponsored research which confirmed a high incidence of transitory mild meningitis. Since that time, government agencies have acted to prevent the importation of single vaccines containing this strain.